Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.


  • Single neuron may carry over 1,000 mutations

  • Sensory feedback shapes individuality to provide equal space for behavioral excellence

  • Tugs and pulls: How a molecular motor untangles protein

  • Enzyme malfunction may be why binge drinking can lead to alcoholism, study finds

  • Scale of gene mutations in human neurons examined

  • Scientific literature overstates psychotherapy's effectiveness in treating depression

  • Glutamate: Essential food for the brain

  • Brain chemical aids tic control in Tourette Syndrome, say researchers

  • New study removes cancer doubt for multiple sclerosis drug

  • Online e-cigarette vendors engage customers using popular internet tools